Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publication [PDF]
Therapeutic Advances in Chronic DiseaseSummary What is this summary about? • This is a summary of a research article published in a medical journal that describes the main results from two studies called TRuE-V1 and TRuE-V2 • These studies looked at the use of ruxolitinib cream to treat ...
David Rosmarin +13 more
doaj +2 more sources
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years [PDF]
Skin Health and DiseaseJohn E. Harris +11 more
doaj +4 more sources
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis. [PDF]
Am J Clin Dermatol, 2023 Ruxolitinib cream 1.5% (OPZELURA™) is a topical formulation of ruxolitinib, a potent, selective inhibitor of Janus kinase (JAK)1 and JAK2. The targeting of these kinases is associated with therapeutic benefits in patients with atopic dermatitis (AD). In two identically designed, multinational, phase III studies in patients aged ≥ 12 years with mild to ...
Hoy SM.
europepmc +3 more sources
Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis [PDF]
Dermatology and TherapyIntroduction Atopic dermatitis (AD) is a chronic, highly pruritic, relapsing inflammatory disease associated with high quality-of-life burden. Topical 1.5% ruxolitinib cream is a selective Janus kinase (JAK)1/JAK2 inhibitor that is well tolerated and ...
Melinda J. Gooderham +13 more
doaj +2 more sources
Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies [PDF]
Dermatology and TherapyIntroduction Two phase 3 trials (TRuE-V1 and TRuE-V2) demonstrated that a topical formulation of the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib significantly improved repigmentation versus vehicle cream in adolescent and adult patients with vitiligo.
Julien Seneschal +9 more
doaj +2 more sources
Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream [PDF]
JID Innovations, 2023 Background: Efficacy of ruxolitinib cream, a topical Jak1/Jak2 inhibitor, was demonstrated in a phase 2 trial in patients with vitiligo. Objective: This study aimed to characterize circulating inflammatory biomarker profiles in patients who demonstrated ≥
Michael D. Howell +8 more
doaj +2 more sources
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. [PDF]
DrugsTopical ruxolitinib 1.5% cream (Opzelura®), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in several countries for use in patients aged ≥ 12 years with non-segmental vitiligo. In the identical phase III TRuE-V1 and TRuE-V2 trials, significantly more ruxolitinib cream recipients were able to achieve statistically significant and ...
Kang C.
europepmc +3 more sources
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. [PDF]
J Eur Acad Dermatol Venereol, 2023 AbstractBackgroundRuxolitinib cream is a topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor.ObjectivesTo report timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis (AD), a highly pruritic inflammatory skin disease.MethodsTwo phase 3 trials (TRuE‐AD1 [NCT03745638]/TRuE‐AD2 [NCT03745651 ...
Blauvelt A +10 more
europepmc +3 more sources
Repigmentation by body region in patients with vitiligo treated with ruxolitinib cream over 52 weeks. [PDF]
J Eur Acad Dermatol VenereolPasseron T +8 more
europepmc +6 more sources
PrescriberRuxolitinib cream is licensed for the treatment of non‐segmental vitiligo with facial involvement in adolescents (≥12 years old) and adults. This article summarises its mechanism of action, the clinical trial evidence of efficacy and its place in therapy.
Steve Chaplin
openalex +2 more sources